Semaglutide TFA 是人胰高血糖素样肽-1 的一个长效类似物，是人胰高血糖素样肽-1 (GLP-1) 受体激动剂。Semaglutide TFA 有潜力用于 2 型糖尿病的研究。

Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.

Solid

GLP-1 receptor.

Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib, Arg) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38±0.06 nM. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1. has not independently confirmed the accuracy of these methods. They are for reference only.

The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs. Semaglutide improves 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairments. In addition, Semaglutide rescues the decrease of tyrosine hydroxylase (TH) levels, alleviates the inflammation response, reduces lipid peroxidation, inhibits the apoptosis pathway, and also increases autophagy- related protein expression, to protect dopaminergic neurons in the substantia nigra and striatum. Moreover, the long-acting GLP-1 analogue semaglutide is superior to liraglutide in most parameters. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight. has not independently confirmed the accuracy of these methods. They

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisturePowder -80°C 2 years；-20°C 1 year

[1]. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844.
[2]. Zhang L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinsons disease mouse model. Neuropeptides. 2018 Oct;71:70-80.

In Vitro: DMSO : 100 mg/mL (23.65 mM; ultrasonic and warming and heat to 60°C)H₂O : 100 mg/mL (23.65 mM; Need ultrasonic)配制储备液